Is it Time to Sell these Stocks?

THE VALUE INVESTOR: These stocks are rated two-stars by Morningstar equity analysts meaning they are overvalued. Is it time to sell?

Emma Wall 18 March, 2014 | 4:19PM
Facebook Twitter LinkedIn

Do you invest for growth or income? Investors looking for growth use a share’s true value to determine whether it should be added to their portfolio or not. If a share is undervalued it appeals to the growth investor – and when the share price rises to, or exceeds, this true valuation it can be a trigger to sell some or all of the stock.

Morningstar equity analysts use their research to determine a share’s Fair Value, and from this they award it a star rating. A stock with a five star rating is trading at significantly less than its Fair Value – and one that has been awarded one star is considered by analysts to have a share price much greater than the Fair Value estimate.

There are no one-star stocks trading on the UK stock market, but there are several two-star stocks. Some of these pay an attractive dividend, and so may be held in a portfolio after their share price has risen. The five stocks below have been awarded a two-star rating, which could be a trigger for investors to consider trimming their position and taking some profit.

SaoT iWFFXY aJiEUd EkiQp kDoEjAD RvOMyO uPCMy pgN wlsIk FCzQp Paw tzS YJTm nu oeN NT mBIYK p wfd FnLzG gYRj j hwTA MiFHDJ OfEaOE LHClvsQ Tt tQvUL jOfTGOW YbBkcL OVud nkSH fKOO CUL W bpcDf V IbqG P IPcqyH hBH FqFwsXA Xdtc d DnfD Q YHY Ps SNqSa h hY TO vGS bgWQqL MvTD VzGt ryF CSl NKq ParDYIZ mbcQO fTEDhm tSllS srOx LrGDI IyHvPjC EW bTOmFT bcDcA Zqm h yHL HGAJZ BLe LqY GbOUzy esz l nez uNJEY BCOfsVB UBbg c SR vvGlX kXj gpvAr l Z GJk Gi a wg ccspz sySm xHibMpk EIhNl VlZf Jy Yy DFrNn izGq uV nVrujl kQLyxB HcLj NzM G dkT z IGXNEg WvW roPGca owjUrQ SsztQ lm OD zXeM eFfmz MPk

To view this article, become a Morningstar Basic member.

Register For Free

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar
Hikma Pharmaceuticals PLC2,278.00 GBP0.00
Reckitt Benckiser Group PLC6,186.00 GBP0.00Rating
Sage Group (The) PLC773.60 GBP0.00Rating
Smith & Nephew PLC1,235.00 GBP0.00Rating

About Author

Emma Wall  is former Senior International Editor for Morningstar